Wedbush Assumes Coverage on Heartware Int'l (HTWR) at Outperform; Getting Ready for April 25
Tweet
Share
E-mailGet Alerts HTWR Hot Sheet
Price: $57.98 --0%
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush assumes coverage on Heartware Int'l (NASDAQ: HTWR) with an Outperform. PT $95.00 (from $105.00).
Analyst, Akiva Felt, said, "The expected Q3:12 US approval of the HVAD for Bridge-to-Transplant (BTT) will be a transformative event for HTWR, in our view, as we believe the device’s best-in-class characteristics will lead to its adoption over Thoratec’s (Nasdaq: THOR)(NEUTRAL) HeartMate II. Although expectations for BTT approval appear to be mostly reflected in HTWR’s current share price, we believe there is 10-20% of additional upside on a positive panel recommendation and subsequent approval."
Also of note, Felt sees the market potential in Destination Therapy (DT), presents long-term investors with compelling value. (expect HTWR U.S. approval in 2015). FY12 EPS loss adjusted from (4.73) to (4.69), sees FY13 loss at (0.17).
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $67.88 yesterday.
Analyst, Akiva Felt, said, "The expected Q3:12 US approval of the HVAD for Bridge-to-Transplant (BTT) will be a transformative event for HTWR, in our view, as we believe the device’s best-in-class characteristics will lead to its adoption over Thoratec’s (Nasdaq: THOR)(NEUTRAL) HeartMate II. Although expectations for BTT approval appear to be mostly reflected in HTWR’s current share price, we believe there is 10-20% of additional upside on a positive panel recommendation and subsequent approval."
Also of note, Felt sees the market potential in Destination Therapy (DT), presents long-term investors with compelling value. (expect HTWR U.S. approval in 2015). FY12 EPS loss adjusted from (4.73) to (4.69), sees FY13 loss at (0.17).
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $67.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
- Leerink Starts Ligand Pharma (LGND) at Outperform
Create E-mail Alert Related Categories
Analyst EPS Change, FDA, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
